RPG Life Sciences Ltd Share Price Today

Actions	Ex-Date	Record-Date
DividendsFinal Dividend of 300% at ₹24/Share	09-Jul-2026	09-Jul-2026
DividendsFinal Dividend of 250% at ₹20/Share	27-Jun-2025	27-Jun-2025
DividendsSpecial Dividend of 50% at ₹4/Share	27-Jun-2025	27-Jun-2025

Mutual Fund Holder	Jul 26 Shares held	Aug 26 Shares held
Unifi Flexi Cap Fund - Regular Plan - Growth	6.57 k	6.57 k no change
Motilal Oswal BSE Healthcare ETF	118	118 no change
Bandhan BSE Healthcare Index Fund - Regular Plan - Growth	63	55 (12.7%)
Motilal Oswal BSE 1000 Index Fund - Regular Plan - Growth	13	13 no change

Kumar Satyam

6 Sep • 5:05 PM · SEBI-Registered Analyst

RPG Life Sciences Eyes Larger API Acquisitions

RPG Life Sciences is scouting for larger API assets as it looks to expand its presence in the active pharmaceutical ingredients business, following acquisitions worth ₹215 crore. Key Highlights • The company is exploring opportunities to acquire larger API assets. • The search comes after completing acquisitions worth ₹215 crore. • The move indicates an intent to further expand its presence in the API segment. Why It Matters Further API acquisitions could help RPG Life Sciences expand its manufacturing capabilities and diversify its pharmaceutical business. The focus on larger assets also suggests that the company is looking beyond its recent ₹215 crore acquisitions for the next phase of expansion. However, the eventual impact will depend on the size, valuation and nature of any assets acquired.

RPGLIFE

Shashank Gupta

6 Sep • 4:44 PM · SEBI-Registered Analyst

RPG Life Sciences expands API business through acquisitions

RPGLIFE

RPG Life Sciences has accelerated its expansion in the active pharmaceutical ingredient (API) segment, committing more than ₹500 crore for acquisitions, manufacturing expansion, product development and regulatory access. The company has completed two acquisitions in recent weeks, including the API and intermediates business of Raghava Life Sciences for up to ₹135 crore. The strategy is aimed at building a larger, integrated API platform through a “buy-and-build” approach. Following the acquisitions, manufacturing capacity has increased from 110 kilolitres to 505 kilolitres, while the product portfolio has expanded from 14 to 45 products. The company is also targeting greater utilisation of the acquired facilities and expansion of its third-party and export customer base. The development could strengthen RPG Life Sciences’ presence in the API market and provide opportunities for revenue growth through improved capacity utilisation, differentiated products and wider market access. However, the financial benefit will depend on successful integration, customer additions and the profitability of the acquired businesses. Investors should monitor acquisition execution, utilisation levels, additional capital requirements and regulatory progress.

Akhilesh Jat SEBI RA

3 May • 8:43 AM · SEBI-Registered Analyst

RPG Life Sciences Q4: Profit Slumps Despite Strong Revenue Growth

RPGLIFE

reported a contrasting Q4 performance on a consolidated YoY basis, with profit plunging 74.5% to ₹29.9 crore compared to ₹117.4 crore last year. The sharp decline was largely due to significantly lower exceptional gains, which stood at just ₹1.1 crore versus ₹109.9 crore in the previous year. However, the company posted healthy revenue growth of 23.6%, reaching ₹176.9 crore from ₹143.1 crore, indicating steady business momentum. Despite the weak profitability, the stock saw strong buying interest, jumping over 13% on April 30, 2025, reflecting notable market activity following the results announcement. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.

Sunil Kotak

30 Apr • 2:06 PM · SEBI-Registered Analyst

RPGLIFE

- Q4FY26 Quarterly Result Announced for RPG Life Sciences Ltd.

RPGLIFE

- Q4FY26 Quarterly Result Announced for RPG Life Sciences Ltd. Pharmaceuticals company RPG Life Sciences announced Q4FY26 results Q4FY26 Financial Highlights: Revenue from Operations: Rs 17,689 lakh in Q4FY26, up by 23.62% compared to Rs 14,309 lakh in Q4FY25 (YoY) and down by 1.74% from Rs 18,003 lakh in Q3FY26 (QoQ). Profit before exceptional items and tax: Rs 3,910 lakh in Q4FY26, up by 56.40% compared to Rs 2,500 lakh in Q4FY25 (YoY) and up by 4.16% from Rs 3,754 lakh in Q3FY26 (QoQ). Net Profit for the period: Rs 2,990 lakh in Q4FY26, a decrease of 74.52% compared to Rs 11,735 lakh in Q4FY25 (YoY) and an increase of 35.11% from Rs 2,213 lakh in Q3FY26 (QoQ) Total Comprehensive Income: Rs 2,998 lakh in Q4FY26 compared to Rs 11,620 lakh in Q4FY25 (YoY) and Rs 2,145 lakh in Q3FY26 (QoQ). FY26 Financial Highlights: Revenue from Operations: Rs 70,752 lakh in FY26, a growth of 8.28% compared to Rs 65,343 lakh in FY25. Profit before tax: Rs 15,420 lakh in FY26, down by 33.79% compared to Rs 23,288 lakh in FY25. Net Profit for the year: Rs 11,517 lakh in FY26, down by 37.15% compared to Rs 18,324 lakh in FY25. Earnings Per Share (EPS): Basic and Diluted EPS for FY26 stood at Rs 69.64 compared to Rs 110.80 in FY25. All this is for information. This is not a buy/sell recommendation. Thank you, Technofunda24

Sunil Kotak

18 Oct • 9:55 AM · SEBI-Registered Analyst

RPGLIFE

- Q2FY26 Quarterly Result Announced for RPG Life Sciences Ltd.

RPGLIFE

Pharmaceuticals company RPG Life Sciences announced Q2FY26 results Revenue from Operations: Rs 181.7 crore compared to Rs 168.9 crore during Q1FY26, change 7.6%. EBITDA: Rs 43.6 crore compared to Rs 40.7 crore during Q1FY26, change 7.1%. EBITDA Margin: 24.0% for Q2FY26. PBT: Rs 38.2 crore compared to Rs 35.4 crore during Q1FY26, change 7.9%. PAT: Rs 28.5 crore compared to Rs 26.3 crore during Q1FY26, change 8.1%. PAT Margin: 15.7% for Q2FY26. Results are better than expected. Thank you, Technofunda24 All this is for information. This is not a buy/sell recommendation. Sunil Kotak (Founder of SHUBH CONSULTANCY - SEBI Registered Research Analyst| INH000015826) Disclaimer: Investments are subject to market risk please read relevant documents before investing. Past performance will not guarantee the future results. My self/may associates do not own any stock discussed here. Me/My associates/My relatives do not have any conflict of Interest in the discussed stock. Me/My associates/My relatives have not received any compensation from the Company in last 12 months. Me/My associates/My relatives do not have holding above 1% in the stock discussed. This is for Intended Recipient only. Advisable to assume that we have recommended this one to our clients.

Kumar Satyam

9 Aug • 9:56 PM · SEBI-Registered Analyst

High-EPS Stocks to Watch – Quick Insights

High Earnings Per Share (EPS) can indicate strong profitability and efficient capital use. Below are select stocks from your list with notable EPS trends: 1. Stellant Securities – EPS ~₹41.2; exceptionally high ROE (~67%) and RoCE (~87%). Small-cap with strong returns but higher volatility risk. 2. HDFC AMC – EPS ~₹121.6; Q1 PAT up 24% YoY to ₹748 cr with EBITDA margin near 80%. Strong asset management franchise. 3. Wealth First Portfolio – EPS ~₹33.9; debt-free with stable profitability. 4. Amal – EPS ~₹30.9; consistent earnings growth, no leverage. 5. RPG Life Sciences – EPS ~₹110.5; robust pharma margins and healthy balance sheet. 6. ICICI Lombard

ICICIGI

– EPS ~₹54.0; strong insurance sector player with steady underwriting performance. 7. UTI AMC – EPS ~₹55.9; improving market share in asset management. 8. GM Breweries – EPS ~₹56.9; high EPS but cyclical liquor sector exposure. 9. Elantas Beck – EPS ~₹167.7; among the highest in the group, niche chemical segment leader. Learnings: EPS alone isn’t enough – check valuations (P/E), growth consistency, and market risks. Small-caps like Stellant can post extraordinary EPS but may lack scalability. Large-caps like HDFC AMC & ICICI Lombard offer stronger institutional coverage and resilience. Sector context matters – financials, manufacturing, and specialty chemicals each have different valuation norms. Investor takeaway: Use high EPS as an initial screen, then assess sustainability, industry trends, and capital allocation before making portfolio decisions.

RPG Life Sciences Ltd. Share Price

Overview

Market Data

Open Price

Prev. Close

Day Low

Day High

52 Week Low

52 Week High

Fundamentals

Quick Bite

Price To Earnings Ratio

Sector PE

PB Ratio

Sector PB

EPS

Dividend Yield

Today's Volume

5 Day Avg. Volume

PEG Ratio

Market Cap.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Mutual Fund Ownership

About RPG Life Sciences Ltd. 👋

Expert Opinions

News & Events

Frequently Asked Questions

What is the share price of RPG Life Sciences Ltd.?

What is the market cap of RPG Life Sciences Ltd.?

Should I buy RPG Life Sciences Ltd. stock now?

What is the 52 week high and low of RPG Life Sciences Ltd.?

Is the RPG Life Sciences Ltd. stock good to buy?

Is RPG Life Sciences Ltd. a good buy for the long term?

Is RPG Life Sciences Ltd. overvalued or undervalued?

What is the PE and PB ratio of RPG Life Sciences Ltd.?